Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
10 2019
Historique:
received: 26 03 2019
revised: 05 06 2019
accepted: 17 06 2019
pubmed: 14 7 2019
medline: 31 3 2020
entrez: 14 7 2019
Statut: ppublish

Résumé

Genetic variations in CRISPR/Cas9 was used to generate human U937 monocytes with A20 DUB-inactivating Genetic disruption of A20 DUB domain in human and murine myeloid cells did not give rise to enhanced NF-κB signalling. Instead, cells with We propose that genetic alterations disrupting the A20 DUB domain mediate increased susceptibility to SLE through the upregulation of

Identifiants

pubmed: 31300459
pii: annrheumdis-2019-215434
doi: 10.1136/annrheumdis-2019-215434
pmc: PMC6788882
doi:

Substances chimiques

Autoantibodies 0
Epitopes 0
NF-kappa B 0
Endopeptidases EC 3.4.-
Tumor Necrosis Factor alpha-Induced Protein 3 EC 3.4.19.12
ubiquitin isopeptidase EC 3.4.99.-
Protein-Arginine Deiminase Type 4 EC 3.5.3.15

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1363-1370

Subventions

Organisme : Medical Research Council
ID : MR/R021406/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MRC000985
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: LO, ZR, RR, LÖ, MR, LFY, SJ, JM, KT, PJ, BC and OV were employees at AstraZeneca Group while performing this study and may have stock/stock options in AstraZeneca. AB received research grant from DISSECT, partly funded by AstraZeneca. LR reports grants and personal fees from Astra Zeneca during the conduct of the study and personal fees from Biogen outside the submitted work. AstraZeneca provided funding to DISSECT for the conduct of this study. The remaining authors declare that they have no competing interests. There are no patents involved.

Références

Nat Commun. 2018 Feb 13;9(1):658
pubmed: 29440643
J Exp Med. 2010 Aug 30;207(9):1853-62
pubmed: 20733033
JCI Insight. 2017 May 18;2(10):null
pubmed: 28515361
JCI Insight. 2017 May 18;2(10):null
pubmed: 28515366
Cell Host Microbe. 2010 Nov 18;8(5):445-54
pubmed: 21075355
Sci Transl Med. 2011 Mar 9;3(73):73ra20
pubmed: 21389264
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9813-8
pubmed: 20439745
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643232
Nat Med. 2016 Feb;22(2):146-53
pubmed: 26779811
EMBO J. 2012 Oct 3;31(19):3845-55
pubmed: 23032186
J Leukoc Biol. 2017 Sep;102(3):775-781
pubmed: 28465447
Nat Genet. 2016 Jan;48(1):67-73
pubmed: 26642243
J Immunol. 2010 Jun 15;184(12):7001-9
pubmed: 20483768
Nature. 2004 Aug 5;430(7000):694-9
pubmed: 15258597
J Immunol. 2011 Jul 1;187(1):538-52
pubmed: 21613614
Thromb Haemost. 2012 Mar;107(3):597-8
pubmed: 22318427
Ann Rheum Dis. 2015 Dec;74(12):2199-206
pubmed: 25104775
Nat Rev Rheumatol. 2014 Nov;10(11):645-53
pubmed: 25072264
Ann Rheum Dis. 2019 Feb;78(2):238-248
pubmed: 30563869
Sci Transl Med. 2011 Mar 9;3(73):73ra19
pubmed: 21389263
Arthritis Res Ther. 2016 Dec 3;18(1):289
pubmed: 27912793
Ann Rheum Dis. 2014 Mar;73(3):483-91
pubmed: 24291655
Nat Med. 2015 Jul;21(7):815-9
pubmed: 26076037
Immunity. 2013 May 23;38(5):896-905
pubmed: 23602765
Nat Chem Biol. 2015 Mar;11(3):189-91
pubmed: 25622091
Genet Test Mol Biomarkers. 2012 Sep;16(9):1105-10
pubmed: 22924496
Nature. 2009 Jun 4;459(7247):717-21
pubmed: 19412164
Nat Genet. 2008 Sep;40(9):1062-4
pubmed: 19165919
Arthritis Res Ther. 2012 Feb 02;14(1):R25
pubmed: 22300536
FEBS Lett. 2010 Jul 16;584(14):3193-7
pubmed: 20541553
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
Inflamm Res. 2012 Jun;61(6):635-41
pubmed: 22402800
Sci Transl Med. 2012 Oct 24;4(157):157ra141
pubmed: 23100627
J Clin Invest. 2013 Jul;123(7):2981-93
pubmed: 23722903
Biochem J. 2004 Mar 15;378(Pt 3):727-34
pubmed: 14748687
EMBO Rep. 2014 Jul;15(7):775-83
pubmed: 24878851
Nat Struct Mol Biol. 2004 Aug;11(8):777-83
pubmed: 15247907
Rheumatology (Oxford). 2013 Mar;52(3):427-37
pubmed: 23148088

Auteurs

Lina Odqvist (L)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Zala Jevnikar (Z)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Rebecca Riise (R)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Lisa Öberg (L)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Magdalena Rhedin (M)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Dag Leonard (D)

Department of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Linda Yrlid (L)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Sonya Jackson (S)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Johan Mattsson (J)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Sambit Nanda (S)

MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.

Philip Cohen (P)

MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.

Axel Knebel (A)

MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.

Simon Arthur (S)

Division of Immunology and Cell Signaling, School of Life Sciences, University of Dundee, Dundee, UK.

Kristofer Thörn (K)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Elisabet Svenungsson (E)

Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden.

Andreas Jönsen (A)

Skåne University Hospital, Department of Clinical Science Lund, Rheumatology, Lund University, Lund, Sweden.

Iva Gunnarsson (I)

Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden.

Karolina Tandre (K)

Department of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Andrei Alexsson (A)

Department of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Alf Kastbom (A)

Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden.

Solbritt Rantapää-Dahlqvist (S)

Department of Public Health and Clinical Medicine/Rheumatology, Umeå Universitet Medicinska fakulteten, Umea, Sweden.

Maija-Leena Eloranta (ML)

Department of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Ann-Christine Syvänen (AC)

Department of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Anders Bengtsson (A)

Skåne University Hospital, Department of Clinical Science Lund, Rheumatology, Lund University, Lund, Sweden.

Patrik Johansson (P)

Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Johanna K Sandling (JK)

Department of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Christopher Sjöwall (C)

Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden.

Lars Rönnblom (L)

Department of Medical Sciences, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Barry Collins (B)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden.

Outi Vaarala (O)

Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca R&D Gothenburg, Mölndal, Sweden vaaralao@medimmune.com.
Respiratory, Inflammation and Autoimmunity Department, MedImmune LLC, Gaithersburg, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH